Clinical Trial Update: Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer [Phase 1]

View source ↗

Summary

Open-label, Phase 1 neoadjuvant trial evaluating nogapendekin alfa inbakicept, sotevtamab, and zabadinostat in combination with gemcitabine and nab-paclitaxel f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Nogapendekin-alfa Inbakicept
• Sotevtamab (AB-16B5)
• Zabadinostat

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Pancreatic Cancer Resectable, Pancreatic Cancer | Phase 1 | Status: NOT_YET_RECRUITING